Drugs / arpraziquantel
arpraziquantel
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02271984 | Oct → Dec 2014 | — | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07262814 | Jul → Oct 2026 expected | opisthorchiasis | Jennifer Keiser | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03845140 | Sep 2019 → Oct 2021 | schistosomiasis | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-03-04 | Merck KGaA, Darmstadt, Germany | First Preschool-Aged Child Receives Arpraziquantel for the Treatment of Schistosomiasis emdgroup.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | arpraziquantel | “Efficacy, safety, and palatability of arpraziquantel (L-praziquantel) orodispersible tablets in children aged 3 months to 6 years infected with Schistosoma in Côte d'Ivoire and...” PMID 36893784 ↗ Mar 20231“ascending doses of arpraziquantel in children infected with Opisthorchis viverrini” NCT07262814 ↗ |
| Known as | (r)-(-)-praziquantel | ChEMBL registry synonym — accepted as the source's own label CHEMBL1235551 ↗ |
| Known as | Arprazicuantel | ChEMBL registry synonym — accepted as the source's own label CHEMBL1235551 ↗ |
| Known as | L-praziquantel | “Efficacy, safety, and palatability of arpraziquantel (L-praziquantel) orodispersible tablets in children aged 3 months to 6 years infected with Schistosoma in Côte d'Ivoire and...” PMID 36893784 ↗ Mar 2023 |
| Known as | L-pzq | ChEMBL registry synonym — accepted as the source's own label CHEMBL1235551 ↗ |
| Known as | MSC2499550A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02271984 ↗ |
| Modality | Small molecule | — CHEMBL1235551 ↗ |
| Route | Oral | “Subjects will receive a single oral dose of MSC2499550A formulation at 20 mg/kg dispersed in water under fed condition in one of the intervention periods.” NCT02271984 ↗ |